AbbVie - Latest News and Investment Deals
Technology Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
ABBV
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
Biotech in 2025: A Retrospective
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
Analysis Finds Efficiencies, Savings of Using a Single Bispecific for DLBCL and FL
Amgen Adds AML Candidate in Deal for U.K.-based Dark Blue: Deals Report
AbbVie Says Immunology Blockbusters Will Be 'Main Drivers' Of Growth Post-Humira
FDA Revises Recommendation on First Full Epcoritamab Dose in R/R DLBCL to Allow Outpatient Monitoring
The Top 10 PharmTech Videos of 2025
Inside NImmune’s Phase 3 Push in Ulcerative Colitis
Proteasomes: A Novel Approach to Target the Immune System
FDA to Meet Novo Nordisk on Troubled Site; AbbVie Buys Drug-Device Factory
CMS's Medicare Price Negotiations Start Round Three
Tenpoint Wins FDA Nod for Combination Presbyopia Eye Drop
Report Says MSD Is in Talks to Buy Revolution Meds
SCHD: Your Complete Guide To The March 2026 Index Reconstitution
9 Companies Hiring Now in Pennsylvania
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
AbbVie, AstraZeneca Lose Appeal in Louisiana 340B Contract Pharmacy Fight
Lilly Strikes Again, Buying CAR-T Firm Orna for $2.4bn
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study
11 Companies Hiring Manufacturing Professionals Now
Former FDA Deputies Land at Lilly, AbbVie; Italy's Angelini Has a New CEO
Hiring Outlook: February Brings First YOY Job Increase Since 2022
10 Companies Hiring IT Professionals Now
Boehringer Signs €1bn+ Deal for Simcere IBD Candidate
2025 Novel Large Molecule FDA Drug Approvals
Hippocratic AI Builds in Life Sciences with Grove AI Buy
IBS Awareness Month 2026: The Hidden Realities of IBS and the IBS Treatment Market
The $500,000 Portfolio To Potentially Pay All Your Bills
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
Johnson & Johnson’s Pipeline Strategy: What Does 2026 Have in Store for the Big Pharma?
The Most Innovative Artificial Intelligence Companies of 2026
JPM26: Galapagos' New CEO Is Here to Finally Turn The Ship Around
Alumis Soars as TYK2 Drug Hits Mark in Psoriasis Trials
AbbVie Turbocharges Its US Investment Promise to $100bn
JCE: Large-Cap Equity Fund With Call Options, 8.15% Yield, And 5.7% Discount
AbbVie, Gubra Post Obesity Data; Regeneron Obesity Drug Succeeds in China
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates
Protagonist’s First Approval Spells Trouble for Pharma’s Immunology Heavyweights
AbbVie Jumps Into PD-1xVEGF Bispecific Race, Pays $650M Upfront to RemeGen
FFA Equity Fund With Call-Overlay, 7.27% Yield, 10% Discount, And Decent Growth
IWF, TSLA, ABBV, NFLX: ETF Inflow Alert
J&J Jumps on the MFN Pricing Train
Bimekizumab Demonstrates Superiority Over Risankizumab in Psoriatic Arthritis Trial
JPM Day 3: Rare Disease in the Spotlight
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
STAT+: Justice Department Backs AbbVie in Its Bid to Overturn a Colorado Law Guiding a Drug Discount Program
JPM: AbbVie Pays $650m Upfront for RemeGen Cancer Drug
